Pulmonary Hypertension

Pulmonary hypertension (PH) is a complex hemodynamic and pathophysiological disorder characterized by an elevated mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg at rest, as measured by right heart catheterization (RHC), or an estimated systolic pulmonary arterial pressure (sPAP) > 30-35 mmHg by Doppler echocardiography. In veterinary medicine, PH is increasingly recognized as a significant complication of various cardiac and respiratory diseases, leading to progressive right ventricular (RV) remodeling, right-sided congestive heart failure (CHF), and increased morbidity and mortality. The disease is classified into five broad categories based on the underlying etiology, as adapted from the World Health Organization (WHO) classification for humans: (1) pulmonary arterial hypertension (PAH), (2) PH due to left heart disease, (3) PH due to lung diseases and/or hypoxia, (4) chronic thromboembolic PH (CTEPH), and (5) PH with unclear multifactorial mechanisms. In dogs and cats, the most common causes are left-sided heart disease (e.g., myxomatous mitral valve disease, dilated cardiomyopathy), respiratory diseases (e.g., chronic bronchitis, pulmonary fibrosis, brachycephalic obstructive airway syndrome), and heartworm disease (Dirofilaria immitis). PH can be classified as pre-capillary (involving the pulmonary arterial bed) or post-capillary (due to elevated pulmonary venous pressure from left heart disease). The clinical consequences include exercise intolerance, syncope, dyspnea, and signs of right-sided CHF such as ascites and jugular venous distention. Early recognition and targeted management are crucial to improve quality of life and survival.

The etiology of pulmonary hypertension in dogs and cats is diverse and often multifactorial. Primary (idiopathic) pulmonary arterial hypertension (PAH) is rare and may have a genetic basis, but most cases are secondary to identifiable underlying conditions. The major etiologies include: (1) Left-sided cardiac diseases: myxomatous mitral valve degeneration (MMVD), dilated cardiomyopathy (DCM), and left-sided congestive heart failure lead to chronic elevation of left atrial pressure, which is transmitted backward to the pulmonary veins and arteries, causing post-capillary PH. (2) Respiratory diseases: chronic bronchitis, pulmonary fibrosis (idiopathic pulmonary fibrosis in West Highland White Terriers), emphysema, and brachycephalic obstructive airway syndrome (BOAS) cause alveolar hypoxia, which triggers hypoxic pulmonary vasoconstriction and vascular remodeling. (3) Heartworm disease (Dirofilaria immitis): adult heartworms reside in the pulmonary arteries, causing endothelial damage, intimal proliferation, thrombosis, and granulomatous inflammation, leading to pre-capillary PH. (4) Chronic thromboembolic pulmonary hypertension (CTEPH): pulmonary thromboembolism (PTE) from various causes (e.g., hyperadrenocorticism, immune-mediated hemolytic anemia, protein-losing nephropathy, neoplasia) can lead to chronic obstruction and remodeling. (5) Congenital systemic-to-pulmonary shunts (e.g., patent ductus arteriosus, ventricular septal defect) cause increased pulmonary blood flow and PAH. (6) Parasitic infections other than heartworm (e.g., Angiostrongylus vasorum in dogs) can cause pulmonary arteritis. (7) Neoplastic diseases: pulmonary carcinoma or metastatic disease can cause vascular obstruction. (8) Toxins and drugs: certain chemotherapeutic agents (e.g., mitomycin C) or toxins (e.g., pyrrolizidine alkaloids) are rare causes. (9) Systemic inflammatory and immune-mediated diseases: systemic lupus erythematosus, polyarteritis nodosa, and other vasculitides can affect pulmonary vasculature. (10) Genetic factors: mutations in genes such as BMPR2, ACVRL1, and others have been identified in human PAH and may play a role in rare canine cases. The exact molecular triggers often involve endothelial dysfunction, imbalance of vasoactive mediators (decreased prostacyclin and nitric oxide, increased endothelin-1 and thromboxane), and activation of inflammatory and proliferative pathways.

Pulmonary hypertension is most commonly diagnosed in dogs, with a higher prevalence in certain breeds and age groups. In dogs, the median age at diagnosis is typically 9-12 years, reflecting the association with degenerative mitral valve disease and chronic respiratory diseases. There is no strong sex predilection, but some studies suggest a slight male predominance. Breed predispositions include small-breed dogs with MMVD, such as Cavalier King Charles Spaniels, Dachshunds, and Poodles. West Highland White Terriers are predisposed to idiopathic pulmonary fibrosis and subsequent PH. Brachycephalic breeds (e.g., Bulldogs, Pugs, French Bulldogs) are at risk due to BOAS. Heartworm disease is endemic in regions with high mosquito populations, and PH is a common sequela in dogs with chronic infection. Cats are less commonly affected, but PH can occur secondary to chronic respiratory disease (e.g., feline asthma, chronic bronchitis), heartworm disease, or congenital heart disease. The exact incidence of PH in dogs and cats is unknown, but it is estimated that up to 30-50% of dogs with MMVD may have some degree of PH, and it is a negative prognostic indicator. In a study of dogs with MMVD, PH (defined as tricuspid regurgitation velocity > 3.0 m/s) was present in 14-30% of cases. The prevalence of PH in dogs with respiratory disease is also significant, with one study reporting PH in 40% of dogs with chronic bronchitis. Geographic variation exists due to heartworm prevalence and other environmental factors.

The pathophysiology of pulmonary hypertension involves a complex interplay of vasoconstriction, vascular remodeling, thrombosis, and inflammation. The pulmonary vasculature normally has low resistance and high compliance. In PH, there is an imbalance between vasodilatory and vasoconstrictive mediators, leading to sustained vasoconstriction. Endothelial dysfunction results in decreased production of nitric oxide (NO) and prostacyclin (PGI2), and increased production of endothelin-1 (ET-1) and thromboxane A2. This imbalance promotes smooth muscle cell proliferation, endothelial cell proliferation, and fibrosis of the vessel wall. Chronic hypoxia, as seen in respiratory diseases, directly causes hypoxic pulmonary vasoconstriction and upregulates hypoxia-inducible factor-1α (HIF-1α), which leads to vascular remodeling. In left heart disease, the elevated left atrial pressure is transmitted backward, causing passive congestion and eventually reactive vasoconstriction and remodeling of the pulmonary arteries. In heartworm disease, the presence of adult worms causes mechanical obstruction, endothelial damage, and an inflammatory response that leads to intimal proliferation and thrombosis. The increased pulmonary vascular resistance (PVR) leads to right ventricular (RV) pressure overload, RV hypertrophy, and eventually RV dilation and failure. The RV failure results in elevated central venous pressure, leading to ascites, hepatomegaly, and peripheral edema. Additionally, PH can cause ventilation-perfusion mismatch, impaired gas exchange, and reduced cardiac output, leading to exercise intolerance and syncope. The progression of PH is often insidious, and compensatory mechanisms initially maintain cardiac output, but eventually decompensation occurs.

Several intrinsic and extrinsic factors predispose animals to the development of pulmonary hypertension. Intrinsic factors include: (1) Breed and genetics: certain breeds have a higher risk due to inherited predispositions to heart disease (e.g., Cavalier King Charles Spaniels for MMVD) or respiratory disease (e.g., West Highland White Terriers for pulmonary fibrosis). Genetic mutations in genes involved in vascular remodeling (e.g., BMPR2) have been identified in human PAH and may be relevant in some canine cases. (2) Age: older animals are more likely to have degenerative heart disease and chronic respiratory conditions. (3) Sex: some studies suggest a slight male predominance, but this is not consistent. (4) Concurrent diseases: chronic kidney disease, hyperadrenocorticism, and diabetes mellitus may contribute to systemic inflammation and vascular dysfunction. Extrinsic factors include: (1) Environmental factors: exposure to cigarette smoke, air pollution, or high altitude (chronic hypoxia) can exacerbate PH. (2) Diet and nutrition: obesity may contribute to respiratory compromise and increased cardiac workload. (3) Infectious agents: heartworm disease is a major risk factor, and other parasites (e.g., Angiostrongylus vasorum) can cause pulmonary arteritis. (4) Medications: certain drugs (e.g., mitomycin C, some appetite suppressants) have been associated with PH in humans and may be relevant in animals. (5) Management factors: lack of regular veterinary care, poor heartworm prevention, and inadequate management of underlying cardiac or respiratory diseases increase the risk of developing PH.

The clinical signs of pulmonary hypertension are often nonspecific and may be masked by the underlying disease. Early signs include exercise intolerance, lethargy, and a mild cough. As PH progresses, more specific signs emerge: (1) Respiratory signs: tachypnea, dyspnea, and cough. The cough may be due to concurrent left-sided heart disease or tracheal collapse. (2) Cardiovascular signs: syncope (often exertional), collapse, and signs of right-sided heart failure such as ascites, jugular venous distention, and hepatomegaly. (3) General signs: weight loss, poor appetite, and weakness. On physical examination, findings may include: a split or loud S2 heart sound (due to increased pulmonary artery pressure), a right-sided systolic murmur (tricuspid regurgitation), a left-sided systolic murmur (mitral regurgitation if concurrent MMVD), a palpable precordial thrill, and arrhythmias. In advanced cases, there may be cyanosis, prolonged capillary refill time, and weak femoral pulses. In cats, signs may be more subtle, with lethargy, inappetence, and respiratory distress. The onset can be acute in cases of pulmonary thromboembolism, with severe dyspnea, tachypnea, and collapse. Chronic cases may present with progressive exercise intolerance and abdominal distension due to ascites. It is important to note that clinical signs may be primarily due to the underlying disease (e.g., cough in MMVD) rather than PH itself.

The differential diagnoses for pulmonary hypertension include conditions that cause similar clinical signs (dyspnea, syncope, ascites) or that may mimic PH on diagnostic testing. Key differentials include: (1) Primary respiratory diseases: chronic bronchitis, pulmonary fibrosis, tracheal collapse, and bronchopneumonia can cause cough and dyspnea, but they do not typically cause syncope or right-sided heart failure unless PH is present. (2) Left-sided congestive heart failure: can cause cough, dyspnea, and exercise intolerance, but the presence of pulmonary edema on radiographs and left atrial enlargement on echocardiography helps differentiate. (3) Pericardial effusion: can cause ascites and jugular venous distention due to cardiac tamponade, but echocardiography reveals pericardial fluid. (4) Right-sided heart failure from other causes: tricuspid valve dysplasia, pulmonic stenosis, or heartworm disease can cause similar signs, but echocardiography and heartworm testing help differentiate. (5) Neoplastic disease: pulmonary neoplasia or metastatic disease can cause respiratory signs and may be seen on radiographs. (6) Thromboembolic disease: pulmonary thromboembolism can cause acute dyspnea and collapse, and may be a cause or consequence of PH. (7) Congenital heart disease: left-to-right shunts (e.g., PDA, VSD) can cause pulmonary overcirculation and eventually PH, but these are typically diagnosed in younger animals. (8) Systemic hypertension: can cause left ventricular hypertrophy and may be associated with PH, but blood pressure measurement helps differentiate. (9) Anemia or polycythemia: can cause exercise intolerance and syncope, but these are usually identified on CBC. (10) Neuromuscular diseases: can cause weakness and collapse, but they are not associated with cardiac or respiratory findings. Definitive diagnosis of PH requires echocardiographic or catheter-based measurement of pulmonary artery pressure.

The diagnostic approach to pulmonary hypertension should be systematic and stepwise. 1. History and physical examination: Obtain a thorough history, including signalment, onset and progression of signs, and any known underlying diseases. Perform a complete physical examination, with special attention to cardiac auscultation (murmurs, arrhythmias, split S2), respiratory examination (crackles, wheezes), and assessment for ascites or jugular venous distention. 2. Baseline laboratory tests: Complete blood count (CBC), serum biochemistry profile, and urinalysis to identify underlying diseases (e.g., hyperadrenocorticism, protein-losing nephropathy) and to assess organ function. 3. Thoracic radiography: Evaluate for signs of left-sided heart disease (left atrial enlargement, pulmonary edema), respiratory disease (bronchial pattern, interstitial pattern), and pulmonary artery enlargement (main pulmonary artery segment bulging, right-sided cardiomegaly). Radiographs may also reveal heartworm-associated changes (enlarged, tortuous pulmonary arteries). 4. Echocardiography: This is the primary diagnostic tool for PH. Measure the tricuspid regurgitation (TR) jet velocity using continuous-wave Doppler to estimate systolic pulmonary artery pressure (sPAP) using the modified Bernoulli equation: sPAP = 4 × (TR velocity)^2 + right atrial pressure (estimated as 5-10 mmHg). A TR velocity > 2.8 m/s (sPAP > 30-35 mmHg) is suggestive of PH. If TR is absent, other echocardiographic indicators include pulmonary artery acceleration time (PAT) and acceleration-to-ejection time ratio (AT/ET), which are inversely correlated with mPAP. Also assess right ventricular size and function, interventricular septal flattening, and right atrial enlargement. 5. Heartworm testing: Perform antigen and microfilaria tests in dogs, especially in endemic areas. 6. Advanced imaging: If available, computed tomography (CT) angiography can be used to assess for pulmonary thromboembolism or pulmonary parenchymal disease. 7. Right heart catheterization: This is the gold standard for confirming PH and measuring mPAP, but it is rarely performed in clinical practice due to its invasiveness. It may be indicated in cases where echocardiographic findings are equivocal or when surgical or interventional therapy is considered. 8. Additional tests: Depending on the suspected underlying cause, consider testing for hyperadrenocorticism (ACTH stimulation test, low-dose dexamethasone suppression test), protein-losing nephropathy (urine protein-to-creatinine ratio), and other endocrine or immune-mediated diseases. 9. Blood gas analysis: May reveal hypoxemia and help assess the severity of respiratory compromise. 10. Biomarkers: NT-proBNP and troponin I can be helpful in assessing cardiac disease and prognosis.

Laboratory findings in pulmonary hypertension are often nonspecific and reflect the underlying disease. Complete blood count (CBC) may show: (1) Erythrocytosis (polycythemia) due to chronic hypoxia, especially in severe PH or respiratory disease. (2) Leukocytosis or leukopenia depending on the presence of infection or inflammation. (3) Thrombocytopenia or thrombocytosis may be seen in cases of thromboembolism or chronic inflammation. Serum biochemistry may reveal: (1) Elevated liver enzymes (ALT, ALP) due to hepatic congestion from right-sided heart failure. (2) Elevated BUN and creatinine if there is concurrent renal disease or prerenal azotemia from decreased cardiac output. (3) Hypoalbuminemia due to protein-losing nephropathy or liver disease. (4) Electrolyte imbalances (e.g., hyponatremia, hyperkalemia) may occur with diuretic therapy or underlying endocrine disease. Urinalysis may show proteinuria, which is important for diagnosing protein-losing nephropathy. Blood gas analysis may reveal hypoxemia (decreased PaO2) and, in advanced cases, hypercapnia. Specific biomarkers: (1) NT-proBNP (N-terminal pro-B-type natriuretic peptide) is often elevated in dogs with PH, reflecting myocardial stretch and is useful for detecting cardiac disease. (2) Cardiac troponin I may be elevated due to myocardial injury. (3) D-dimer may be elevated in cases of thromboembolism. (4) Heartworm antigen and microfilaria tests are positive in heartworm disease. (5) Endocrine testing (ACTH stimulation, low-dose dexamethasone suppression) may be indicated if hyperadrenocorticism is suspected. (6) Serology for Angiostrongylus vasorum (Baermann fecal examination or antigen test) should be considered in dogs with respiratory signs and coagulopathy. (7) In cats, feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) testing may be considered.

Imaging plays a crucial role in the diagnosis and management of pulmonary hypertension. Thoracic radiography: Findings may include: (1) Right-sided cardiomegaly: increased sternal contact of the heart, right atrial enlargement (bulging of the right atrial border), and right ventricular enlargement (reverse D-shaped heart on DV view). (2) Main pulmonary artery segment bulging (at the 1-2 o'clock position on the DV view). (3) Enlarged, tortuous pulmonary arteries, especially in heartworm disease. (4) Signs of left-sided heart disease (left atrial enlargement, pulmonary edema) if PH is secondary to left heart disease. (5) Interstitial or bronchial patterns if concurrent respiratory disease. (6) Ascites may be seen as loss of abdominal detail. Echocardiography: This is the most valuable imaging modality. Key findings include: (1) Tricuspid regurgitation (TR) with a high-velocity jet (>2.8 m/s) on Doppler. (2) Pulmonary artery acceleration time (PAT) < 80 ms and AT/ET ratio < 0.3 are suggestive of PH. (3) Right ventricular hypertrophy (RV free wall thickness > 5 mm in dogs) and dilation. (4) Right atrial enlargement. (5) Interventricular septal flattening (D-shaped left ventricle in short-axis view) due to RV pressure overload. (6) Pulmonary artery dilation. (7) In heartworm disease, worms may be visualized in the pulmonary arteries as parallel echogenic lines. (8) Assessment of left heart function to identify underlying left-sided disease. Computed tomography (CT): CT angiography can be used to evaluate for pulmonary thromboembolism, pulmonary parenchymal disease, and to measure pulmonary artery diameter. It is particularly useful in cases where echocardiography is inconclusive. Magnetic resonance imaging (MRI) is rarely used but can provide detailed anatomical information. Fluoroscopy may be used to assess dynamic airway collapse in brachycephalic breeds. Endoscopy is not directly useful for PH but may be used to evaluate the respiratory tract for underlying disease.

Cytology and histopathology are not typically required for the diagnosis of pulmonary hypertension, but they may be helpful in identifying underlying causes. Bronchoalveolar lavage (BAL) cytology may reveal inflammatory cells (neutrophils, eosinophils) in cases of chronic bronchitis or parasitic infection. In heartworm disease, microfilariae may be seen on blood smears or in BAL fluid. Histopathology of lung tissue (obtained via biopsy or at necropsy) may show: (1) Intimal proliferation and fibrosis of pulmonary arteries. (2) Medial hypertrophy of the tunica media. (3) Plexiform lesions (in severe PAH). (4) Thromboemboli in the pulmonary vasculature. (5) Inflammatory infiltrates in cases of vasculitis. (6) Evidence of underlying disease, such as pulmonary fibrosis or neoplasia. Histopathology of the right ventricle may show hypertrophy and fibrosis. In cases of suspected pulmonary thromboembolism, histopathology may reveal organized thrombi. Special stains (e.g., elastic Van Gieson) can help assess vascular remodeling. However, due to the invasiveness of lung biopsy, histopathology is rarely performed antemortem.

The treatment of pulmonary hypertension should be directed at the underlying cause whenever possible, along with specific therapy to reduce pulmonary arterial pressure and manage clinical signs. The following is a comprehensive approach: 1. Emergency stabilization: In animals with acute, severe PH or right-sided heart failure, oxygen supplementation, diuretics (furosemide 1-2 mg/kg IV or SC q8-12h), and vasodilators may be needed. 2. Treatment of underlying disease: (a) Heartworm disease: Use the American Heartworm Society protocol, including adulticide therapy (melarsomine 2.5 mg/kg IM q24h for 2 days), macrocyclic lactones, and doxycycline (10 mg/kg PO q12h for 30 days). (b) Left-sided heart disease: Manage with pimobendan (0.3 mg/kg PO q12h), ACE inhibitors (enalapril 0.5 mg/kg PO q12h), and diuretics as needed. (c) Respiratory disease: Treat with bronchodilators (e.g., theophylline 10 mg/kg PO q12h), corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q24h), and oxygen as needed. (d) Thromboembolism: Anticoagulant therapy with clopidogrel (2-4 mg/kg PO q24h) or low-molecular-weight heparin (e.g., enoxaparin 1 mg/kg SC q12h). 3. Specific pulmonary vasodilators: (a) Sildenafil (Viagra) is the most commonly used drug in veterinary medicine. Dose: 1-3 mg/kg PO q8-12h. It is a phosphodiesterase-5 inhibitor that increases cyclic GMP, causing pulmonary vasodilation. (b) Pimobendan (0.3 mg/kg PO q12h) has both inotropic and vasodilatory effects and may be beneficial in PH, especially when left-sided heart disease is present. (c) Tadalafil (1 mg/kg PO q24h) is another PDE-5 inhibitor with a longer duration of action. (d) Amlodipine (0.05-0.1 mg/kg PO q24h) is a calcium channel blocker that may be used in some cases, but it can cause systemic hypotension. (e) Prostacyclin analogs (e.g., treprostinil) are not commonly used in veterinary medicine due to cost and complexity. (f) Endothelin receptor antagonists (e.g., bosentan) are used in humans but are not widely used in animals. 4. Management of right-sided heart failure: If ascites or edema is present, use diuretics (furosemide 1-2 mg/kg PO q8-12h) and consider abdominal drainage for severe ascites. 5. Supportive care: (a) Oxygen therapy for hypoxemia. (b) Nutritional support with a balanced diet, possibly low-sodium. (c) Exercise restriction to reduce oxygen demand. (d) Weight management if obese. 6. Surgical/interventional options: In cases of congenital shunts, surgical correction may be possible. In severe, refractory PH, lung transplantation is not feasible in veterinary practice. 7. Monitoring: Regular rechecks to assess response to therapy and adjust dosages.

The prognosis for pulmonary hypertension varies depending on the underlying cause, severity, and response to therapy. In general, PH is a progressive disease with a guarded to poor prognosis, especially if right-sided heart failure is present. Median survival times in dogs with PH have been reported to be 6-12 months, but some dogs may live longer with appropriate treatment. Negative prognostic indicators include: (1) Presence of right-sided heart failure (ascites, jugular distention). (2) Severe PH (TR velocity > 4.5 m/s or sPAP > 70 mmHg). (3) Lack of response to sildenafil therapy. (4) Underlying diseases such as pulmonary fibrosis or neoplasia. (5) Concurrent left-sided heart failure. (6) Syncope at presentation. (7) Elevated NT-proBNP levels. In dogs with PH secondary to MMVD, the presence of PH is associated with a worse prognosis compared to those without PH. In heartworm disease, PH may improve after successful adulticide therapy, but chronic changes may persist. Cats with PH generally have a poor prognosis, especially if associated with respiratory disease. Early diagnosis and aggressive management of the underlying cause and PH itself may improve quality of life and survival.

Regular follow-up is essential for managing pulmonary hypertension. Recommended schedule: (1) Initial recheck: 1-2 weeks after starting therapy to assess clinical response and adjust drug dosages. (2) Monthly rechecks for the first 3 months, then every 2-3 months thereafter. (3) At each recheck, perform a physical examination, including body weight, heart rate, respiratory rate, and assessment for ascites or edema. (4) Serial echocardiography: Repeat echocardiography every 3-6 months to monitor TR velocity, right heart size, and function. (5) Blood pressure monitoring: Check systemic blood pressure regularly, especially if using vasodilators. (6) Laboratory monitoring: CBC, biochemistry profile, and urinalysis every 3-6 months to monitor organ function and detect side effects of medications. (7) Heartworm testing: In heartworm disease, repeat antigen testing 6-12 months after treatment to confirm clearance. (8) Adjust medications as needed: Sildenafil dose may be titrated based on clinical response and echocardiographic findings. (9) Owner education: Instruct owners to monitor respiratory rate and effort at home and to seek immediate veterinary care if signs worsen. (10) Long-term management: Continue treatment for the underlying disease and PH indefinitely. In cases of heartworm disease, maintain heartworm prevention. In cases of left-sided heart disease, follow standard heart failure management guidelines.

Pearls: (1) Always consider PH in any dog with syncope, especially if there is a heart murmur or respiratory disease. (2) A loud, split S2 heart sound is a classic finding of PH. (3) Echocardiographic measurement of TR velocity is the most reliable noninvasive method to diagnose PH; a velocity > 2.8 m/s is significant. (4) Sildenafil is the first-line treatment for PH in dogs; start at 1 mg/kg PO q8h and titrate up to 3 mg/kg if needed. (5) In heartworm disease, PH may improve after adulticide therapy, but chronic changes may persist. (6) Pimobendan is beneficial in PH, especially when left-sided heart disease is present. (7) Always rule out left-sided heart disease as a cause of PH before starting specific pulmonary vasodilators. (8) In cats, PH is often underdiagnosed; consider it in cats with respiratory distress and a heart murmur. Pitfalls: (1) Failing to diagnose PH because TR is absent; use other echocardiographic indices (PAT, AT/ET) if TR is not present. (2) Using sildenafil in a hypotensive patient without monitoring blood pressure. (3) Overlooking underlying causes such as heartworm disease or hyperadrenocorticism. (4) Using diuretics aggressively in PH without right-sided heart failure, which can decrease preload and worsen cardiac output. (5) Assuming that a normal thoracic radiograph excludes PH; echocardiography is essential. (6) Not monitoring for side effects of sildenafil, such as gastrointestinal upset or hypotension. (7) Failing to recheck echocardiography to assess response to therapy. (8) In cases of pulmonary thromboembolism, not using anticoagulants, which can be life-saving.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used for pulmonary hypertension in dogs and cats: 1. Sildenafil (Viagra): Dogs: 1-3 mg/kg PO q8-12h. Start at 1 mg/kg q8h and increase as needed. Cats: 1-2 mg/kg PO q12h. It is a PDE-5 inhibitor that causes pulmonary vasodilation. Side effects include hypotension, gastrointestinal upset, and flushing. 2. Tadalafil (Cialis): Dogs: 1 mg/kg PO q24h. Longer-acting PDE-5 inhibitor. 3. Pimobendan (Vetmedin): Dogs: 0.3 mg/kg PO q12h, given 1 hour before food. It has positive inotropic and vasodilatory effects. Cats: 0.1-0.3 mg/kg PO q12h. 4. Amlodipine (Norvasc): Dogs: 0.05-0.1 mg/kg PO q24h. Cats: 0.625-1.25 mg/cat PO q24h. Calcium channel blocker; use with caution in PH as it may cause systemic hypotension. 5. Furosemide (Lasix): Dogs: 1-2 mg/kg PO, SC, IV q8-12h as needed for right-sided heart failure. Cats: 1-2 mg/kg PO, SC, IV q12-24h. 6. Enalapril (Enacard): Dogs: 0.5 mg/kg PO q12h. ACE inhibitor; used for left-sided heart disease. Cats: 0.25-0.5 mg/kg PO q12h. 7. Clopidogrel (Plavix): Dogs: 2-4 mg/kg PO q24h. Antiplatelet agent; used for thromboembolism. Cats: 18.75 mg/cat PO q24h. 8. Enoxaparin (Lovenox): Dogs: 1 mg/kg SC q12h. Low-molecular-weight heparin; used for acute thromboembolism. 9. Doxycycline: Dogs: 10 mg/kg PO q12h for 30 days for heartworm disease. 10. Melarsomine (Immiticide): Dogs: 2.5 mg/kg IM q24h for 2 days (two injections) or 3 injections (2.5 mg/kg IM, then 2.5 mg/kg IM 1 month later, then 2.5 mg/kg IM 24h later). 11. Prednisone: Dogs: 0.5-1 mg/kg PO q24h for respiratory disease. Cats: 1-2 mg/kg PO q24h. 12. Theophylline: Dogs: 10 mg/kg PO q12h. Cats: 15-20 mg/kg PO q24h. Bronchodilator. 13. Oxygen therapy: Administer via flow-by, mask, or oxygen cage as needed. 14. In emergency cases, consider IV vasodilators such as nitroprusside (0.5-10 mcg/kg/min CRI) or hydralazine (0.5-2 mg/kg PO q12h), but these are rarely used. Always adjust dosages based on renal and hepatic function, and monitor for drug interactions.

Evidence-based literature on pulmonary hypertension in dogs and cats is growing. Key studies and consensus guidelines include: (1) The ACVIM consensus statement on the diagnosis and treatment of pulmonary hypertension in dogs and cats (2015) provides evidence-based recommendations. It defines PH as a TR velocity > 2.8 m/s and recommends sildenafil as the first-line treatment. (2) A study by Kellihan et al. (2015) evaluated the use of sildenafil in dogs with PH and found significant improvement in clinical signs and exercise tolerance. (3) A study by Johnson et al. (1999) reported that PH is a negative prognostic indicator in dogs with MMVD. (4) A study by Pyle et al. (2004) found that PH is common in dogs with chronic bronchitis and is associated with worse outcomes. (5) A study by Glaus et al. (2004) evaluated the use of pimobendan in dogs with PH and found beneficial effects. (6) A study by Nakamura et al. (2011) investigated the use of tadalafil in dogs with PH and found it to be effective. (7) A study by Borgarelli et al. (2008) evaluated the prevalence of PH in dogs with MMVD and found it to be around 30%. (8) A study by Serres et al. (2006) evaluated the use of sildenafil in dogs with PH and found that it improved quality of life. (9) A study by Visser et al. (2016) evaluated echocardiographic indices for the diagnosis of PH and found that PAT and AT/ET are useful. (10) The American Heartworm Society guidelines (2018) provide recommendations for the treatment of heartworm disease, which is a common cause of PH. (11) A study by Esteve et al. (2015) evaluated the use of NT-proBNP as a biomarker for PH in dogs and found it to be elevated in affected dogs. (12) A study by Guglielmini et al. (2010) evaluated the prognostic value of echocardiographic parameters in dogs with PH. Overall, the evidence supports the use of sildenafil and pimobendan for the treatment of PH, and emphasizes the importance of diagnosing and treating the underlying cause.